International Journal of Current Pharmaceutical Research

ISSN- 0975-7066 Vol 13, Issue 5, 2021

Review Article

ROLE OF MICRONUTRIENTS IN HEART DISEASES

NAMRATA KHAIRNAR[1], PRASHANT PINGALE[2*], SUNIL AMRUTKAR[3]

[1,2*]Department of Pharmaceutics, [3]Department of Pharmaceutical Chemistry, Gokhale Education Society's Sir Dr. M. S. Gosavi College of Pharmaceutical Education and Research, Nashik 422005, Maharashtra, India
Email: prashant.pingale@gmail.com

Received: 04 May 2021, Revised and Accepted: 02 Jul 2021

ABSTRACT

Heart disease is a common occurrence in older patients in the civilized culture, and the rate is predicted to rise as the software advances. Patients with heart disease should be intended to eat a salt-free diet to lose adiposity. Diet is also critical for heart disease patients; those with nutrition deficits have a low deep prognosis. A growing body of research indicates a correlation between heart disease and a lack of micronutrients. Repairable heart disease has been linked to thiamine and selenium deficiency. Micronutrients and heart disease may, nevertheless, have a more moderate association, according to recent research. This article looks at studies that looked at micronutrient consumption, supplement effectiveness, and micronutrient ingestion in heart disease patients, with an emphasis on retinol, ascorbic acid, a fat-soluble vitamin, vitamin B1, other B vitamins, cholecalciferol, folate, iron, and copper. Because aging is the leading cause of coronary heart disease, treatments intended to reduce down the aging process or improving life expectancy are distinctly different from their standards for the treatment of coronary heart disease. Altering risky life decisions which might relate to aging and coronary heart diseases, such as nicotine usage, obesity, and unique lifestyles, is increasingly become part of the quality of practice.

Keywords: Micronutrients, Heart, Nutrition, Vitamins

DOI: https://dx.doi.org/10.22159/ijcpr.2021v13i5.1880 Journal homepage: https://innovareacademics.in/journals/index.php/ijcpr

INTRODUCTION

Micronutrient genetic condition is significant societal medical-related issues to some contributors to the pathophysiology, progression, death, and coronary disorder drawbacks of all chronic conditions, excluding cardiovascular diseases (CVD). CVD is the primary cause of mortality and morbidity globally, accounting for more than 40% of all deaths, and is now on the rise in both developed and developing nations [1]. CVD is expected to impact more than 23 million people over the year. Despite the reality that opioid therapy for specific risk factors for heart disease has proved to be highly effective, current research shows that only certain types of care are capable of reaching optimum dosage levels. This method emphasizes the importance of promoting and preventing CVD therapy as a key step in obtaining the best outcomes [2]. Doctors and dieticians are still searching for new ways to handle cardiovascular disease, such as eating a diet high in micronutrients and antioxidants (fruits and vegetables). Nevertheless, whether made target cardiovascular disease and whether micronutrient enrichment may slow or remove the series and risks associated with cardiovascular diseases in those at harm remains to be seen and continues to cause problems among those that have already been infected [3]. The correlation between meds and cardiovascular diseases continues to be a significant research subject. There have been numerous experiments, and many more are still underway. Present experiments are being related to research studies about the action of such micronutrients in the body, which could provide further knowledge about the potential effect of micronutrient supplements in the main-adjuvant therapy of cardiovascular diseases [4].

Previous medical studies with such micronutrients have found important links between deficiency states and cardiac risk factors, although others have found the opposite. For example, the cardiac result preventive analysis project, the Cambridge heart antioxidant research, the Norwegian vitamin study, and the western Norway B vitamin intervention study all found no proof of a correlation between vitamin B and heart attacks [5]. Supplementing of B vitamins has been found to lower the risk of a heart attack. All such debates have sparked national outrage and may have influenced micronutrient consumption, resulting in differing patterns in micronutrient ingestion around the globe. Whenever the impact of poorly modified predictor variables, including such differences in sample nature and limitations, such as unexpected analytical techniques, is recalled, therefore, the opposite research findings can be solved doses that are unknown specific susceptible elements; diversity and source of micronutrients; base micronutrient level environmental conditions; micronutrient correlations; a lack of micronutrient combination; and a slew of other problems they are being found to have consequences that tend to be close to some of those seen in the extent of previously reported health impacts [6].

Discovery of micronutrients

It's worthwhile to think about some assumptions about micronutrient exploration. This also was known as a consequence of degradation conditions that existed in numerous parts of the planet. Medications of individual foods, initially, and then, once psychoactive ingredient factors have been explained, supplementation of the specific chemical compounds themselves can benefit. Iodine and cretinism, thiamine and beriberi, and, of course, vitamin C and scurvy are all sources, but they are all well detached throughout all diet texts. In the seventeenth and eighteenth centuries, while scurvy was a serious condition, long sea voyages were responsible for the genocide of thousands of warships per year [7]. In 1748, James Lind, an Edinburgh practitioner who served as a physician on a Royal Navy ship, performed the first showing up the scientific review of diet. He grouped the 12 scurvy warships into certain 2 groups, every receiving preferential treatment: team one received cider every day, while the second group received sulphuric acid in ethanol. Four tablespoons of vinegar are completed 3 times a day by group three, a pint of saltwater for team four, two oranges and one lemon for team five, and nutmeg and barley water for group six. For a week then, only team five had progressed to the point that one sailor was allowed back to daily duties and another was given command of the remaining 10 sailors. This style of discovery eventually led to the detailed process of micronutrients, allowing us to reach the point where we are now, with such a thorough understanding of the chemical composition and methodology, as well as the best natural habitats for all vitamins, both fat and water-soluble, and important trace minerals [8].

Evolutionary nutrition

Vitamin D

UV rays, which convert 7-dehydrocholesterol to vitamin D, are predominantly responsible for the synthesis of vitamin D. Vitamin D can be obtained from a daily intake in small amounts. Vitamin D3 (found in fish and processed foods) and vitamin D2 (found in plant species) are two examples. D vitamins deficiency is much more usual in heart failure patients other than maturity level stable people, according to several reports. Vitamin D deficiency tends to have a multifactorial impact on the pathogenesis of HF, including impact on the renin-angiotensin-aldosterone system and the associated high blood pressure, the asymmetrical left side of the heart conformation, epithelium activity, and inflammatory processes, including tumor necrosis components [9]. In a range of clinical studies and randomized controlled studies, mean serum 25 (OH) levels of vitamin D in patients with heart failure were found to be slightly lower than in stable operators. When Heart failure sufferer with antibody fat-soluble vitamin extent of 10 mg/ml was comparable to others with antigen 25-hydroxylase vitamin D levels of>20 mg/milliliter, those with greater LV volumes and lowered LV systolic effect had wide Left ventricular sizes and lesser Left Ventricular pulsation [10]. Antigen 25-hydroxylase calciferol and mortality were discovered to have a weak relationship. The sterol extent of inferior antigen 25-hydroxylase has been proven to have a favorable association with LV activity [11]. In another study, 25–hydroxylase D vitamin inside 100 individuals including extreme Heart failure which being tested as a heart immigrant. As per the reviewers, the united network for organ sharing condition one patients found substantially inferior antibody 25-Hydroxylase ergocalciferol status [12].

Antibody 25-hydroxylase vitamin D levels have also been linked to signs of decreased exercise resistance as determined by peak oxygen intake (VO2 peak). The result of calciferol alternate on Heart Failure effect has yielded inconsistent findings in randomized controlled trials. Strolling Heart failure individuals with New York Heart Association Class 2 or 4 indications exist randomized to collect 40-milligram cholecalciferol plus 200 milligrams a daily dosage of calcium or placebo plus 505-milligram calcium every day for eight weeks with one trial [13]. While compared with control, the research department shows a significant rise in average 25-hydroxylase fat-soluble vitamin extent. About the fact that supplements did not result in substantial interchange natriuresis peptide concentrations, abdomen rates, or Left Ventricular action, sufferer takes it had elevated serum concentration higher levels of its anti-inflammatory cytokines concentrations as to the Tumor necrosis factor cytokine, two interactions did not vary substantially in terms of natriuretic peptide levels, LVEF, or cardiovascular abundance and distribution. Both studies demonstrated a strong rate of survival after six weeks of check-out. Small vitamin D quantity inside restriction community, besides the large proportion of dropout rate, occur significant testing drawbacks that could have influenced the results [14].

The second looked at how supplements impacted physical aged people's adaptive potential Patient accompanied by congestive heart failure who had been diagnosed with Inadequacy of calciferol throughout history. 103 individuals for Heart failure pulse rate (span Seventy and aged) Class 2–3 of the New Year Heart Association evaluated at baseline and after ten weeks. To consider an oral dosage of 25-hydroxyvitamin 500 levels and inactive drug, participants were given indications [15].

The calciferol categorizes 25–hydroxyl vitamin D3 quantity were slightly higher than the control teams. Nevertheless, there was also no substantial gap among groups in the seven-walk study. Patients in the counseling group have reported that their condition was deteriorating, according to Minnesota live with cardiovascular disease report [16].

Vitamin B

Vitamin-B is a solvable water vitamin that occurs as an essential transferase inside the citric acid cycle and thus is critical, especially for the growth of nucleotide. These include vitamin B1, vitamin B2, ascorbic acid, folate, cyanocobalamin, nicotinic acid, pantothenate, arginine; entirely these occur as fundamental sources of nutrition particularly must be the regular compensations for B vitamin inactive people that were later approved were insufficient for patients with heart failure. Loop diuretics, in particular, increase water-soluble vitamin deficiency in the kidneys. Thiamine deficiency has been reported to affect between 13 and 33 % of patients with chronic heart failure. Thiamine loss has been related to hospitalization, diarrhea, and loop diuretics as people grow older. Extreme thiamine deficiency, on the other hand, will lead to high heart failure attributable to enlarged vasoconstriction [17]. It is, nevertheless, rare in this day and age. Related findings have shown that thiamine supplementation improves both LV and cardiovascular function. Seligmann *et al.* observed a Thirteen percent growth in LVEF and 30 millimeters of mercury reduction inside blood pressure later seven days of the endogenous B complex. A mixture of endogenous B complex for 216 h following buccal aneurin as 42 d resulting around a 26 % increase inside left ventricular ejection fraction around 30 percentage as for instances, so according to study. In a spontaneous, double-blind, combination sample of 9 patients with LVEF only around 40%, Steinberger *et al.* Found similar results. They observed a 3.9 percent increase in LVEF from 29.5 percent to 32.8 percent after 4 w of thiamine supplements [18]. Although these findings indicate that thiamine supplements can improve Heart failure surrogate access points, further studies are needed to determine the effect on clinical results.

Vitamin B2, pyridoxal, folate, as well as cyanocobalamin deficiency it was even identified nearby the Heart failure community. Hepatoflavin, vitamin B12, along folate are also involved inside triglyceride synthesis, with cyanocobalamin that was exhibited lead to increase epidermal dysfunction during diabetes and Hypertension victims [19].

Cobalamin can be important specific markers for fluid overload in metabolic acidosis myocardial infarction cardiac disorders, as per studies. A recent Japanese study found a reversed connection in the middle of folate induction along with the incidence of heart disease, especially heart failure. Also, there is little evidence to prove the use of such B-complex vitamins to increase Heart failure consequences [20].

Coenzyme Q10

CoQ10 (ubiquinone) is a lipid-soluble quinone present mainly in saturated fat, seafood, and fish. CoQ10 has positive effects by the removal of oxidative burden and alteration of body equilibrium due to its relatively elevated plasma and myocardial behaviors in healthy people without heart disease [21].

While several cases are reported that indicate a potential function for coq10 supplements in Heart failure, the majority among themselves exist single few trials with just a combination of results findings. In insignificant randomized, dose-ranging, comparative experiments of 59 victims with heart failure, Kata established not all major differences within Left ventricular ejection Factor, peak oxygen consumption, or recreation sympathy afterward regular disposal of 800 milligrams of Coenzyme Q10 for seven months [22].

Belardinelli *et al.*, Discovered a large change in the Ventricle phase and peak VO2 after taking coq10. In contrast to studies, this one used a stronger dose of coq10 (300 mg), and the majority of participants had milder cardiovascular disease. Two main meta-analyses of CoQ10 supplementation in Heart failure have been conducted to date, both of which came to different consequences [23].

Fotino *et al.* discovered that supplementing with CoQ10 improved the LV mechanism and increased peak VO2. This study used a stronger dose of CoQ10 (300 mg), and the majority of patients had less extreme CHF than the prior one. In recent times, three wide meta-analytics of Coenzyme Q10 supplements inside Heart failure were released, both revealing different results [24]. During the initial case-control, Sonja looked at a Fourteen dose-ranging, active-controlled study of CoQ10 implementation within patients with cardiovascular disease. Systolic discharge, cardiovascular

performance, left ventricular Ejection Fraction, cardiology output, and systolic quantities; indication increased significantly dramatically in patients with heart failure who obtained CoQ10 [25].

Sander *et al.* has recently undertaken a meta-analysis in which 11 participants looked at the effects of coenzyme Q10 supplementation in heart disease patients. The analysis of Soja and Mortensen is significant. The structural, operational, and hemodynamic specifications examined included LVEF, heart rate, cardiac index, SV, and stroke inventory. In nine of twelve experiments, LVEF was improved by 3.7 percent [26]. Various situations saw a significant improvement in heart function and stroke index. There was no significantly serious change in cardiovascular index or SV, unlike Sonja and. Differences in LVEF were typically more severe in subset projections in studies that did not include NYHA, individuals in class IV, proceeding beyond ACE inhibitor medication, along with instances targeted solely at Neurogenic myocardial infarction sufferers [27].

The bulk of spontaneous repressed CoQ10 sessions in Heart failure took place at a period when Angiotensin-converting enzyme, beta-interferon, and mineralocorticoid exist frequently employed [28].

Other micronutrients

Trace metals, namely alkali metal, aerugo, along magnesium, are essential for public health. Over the previous 2 centuries, consequence particular in define components on long-suffering along with heart failure has been a major issue. Heart failure patients' urine contains lower levels of and selenium, according to several retrospective studies [29].

In comparison to initial studies of widespread nutritional deterioration, data on copper levels in people with cancer indicates an overall serum level. According to one study, Heart failure patients with high copper levels had a higher risk of death and hospital treatment than those with low copper concentrations. In a recent survey, selenium and CoQ10 were linked to lower levels of NT-pro BNP, lower mortality, and improved cardiovascular function in elderly people [30].

Vitamin A deficit or supplementation in heart disease is not well known. Vitamin A serum levels in patients with heart failure were shown to be irrelevant to healthy living standards, according to a new report.

Heart Failure patients have lower levels of Calcium, according to clinical findings, and de Lorgeril *et al.* and Demi bag *et al.* found a connection between serum vitamin C concentrations and LVEF in their research. Some others discovered that oxidative stress causes significant differences in the vasodilator reaction to dobutrex in baroreceptors myocardial infarction [31].

Ascorbic acid appurtenance enhances epithelial efficiency by reducing reactive oxygen species and increasing NO output. While no researchers have examined ascorbic acid supplements within Heart failure, an investigation that included elevated amounts of important micronutrients especially incorporate Vitamin C found substantial drops within LVEDV and LVES.

Strong claims that antioxidant therapy can reduce the risk of heart failure, research on vitamin E in HF has been limited. Primary retrospective trials showed a little gap in vitamin E concentrations among Heart failure, but two significant research reported that people who take long-term vitamin E supplementation had a lower risk of Heart failure and Heart failure hospital treatment [32].

L-Carnitine

The amino acid sequences leucine and phenylalanine make up levocarnitine, which can move trans-fatty acid from cytosol to the cytoplasm. Glycolysis, the Krebs cycle, and glycogen synthesis are also impaired by it.

An l-carnitine precursor called propionyl-l-carnitine has also been linked to improved glucose oxidation and contractile control. L-carnitine is used in the use of trans fat and blood sugar by a significant cardiac infarction. Lower reperfusion levocarnitine extent is associated with congestive heart failure. Nonetheless, study into significant aids of levocarnitine supplements inside heart failure has produced mixed results [33].

Impacts of l-carnitine plasma concentrations in chronic kidney disease patients with heart failure have been studied, with some displaying elevated or normal rates. Serrati *et al.* Found that giving 1800 milligram of levocarnitine towards 19 cases with New York Heart Association class two complications along with stable left ventricular activity resulted in improved liver function. Others who acquired heartbeat variables via echocardiograms at 13 w over-performed once that acquired at least in addition to once which acquired a placebo. Ueland registered hemoglobin concentrations of levocarnitine (besides some of those which analogs together with derivative products) in 183 heart disease patients and 11 stable monitors, as well as predicted values [34]. In a study conducted by Song *et al.*, the concentrations of free levocarnitine and its racemate l-palmitoyl carnitine being found to be associated along with natriuretic peptide tests and New York Heart Association functional class. Fortunately, only palmitoyl-carnitine was related to major adverse reactions, mostly during follow-up. Those last findings indicate that palmitoyl-carnitine could be more informative than l-carnitine and, as a consequence, must be studied further in upcoming l-carnitine research [35]. In terms of potential impact, the evidence available on l-carnitine supplements in heart failure seems to be positive. A larger randomized controlled trial is needed to prove the effects of l-carnitine supplements in heart failure [36].

Vitamin C

According to a 5 y follow-up study, increased percentages of vitamin C consumption were just as closely linked to mortality from stroke as was diastolic blood pressure. The oxidation of low-density lipoprotein has also been identified as among the contributing factors in the development of atherosclerosis. Pre-treatment with vitamin C then use oxidized low-density lipoproteins [37].

In a hamster model, lipoproteins inhibited platelet aggregation to the endothelial cells and the development of leukocyte-platelet aggregate particles. High blood pressure patients have fewer acetylcholine-induced vasodilator output, which is partly invalidated by vitamin C, and ascorbic acid supplements can decrease blood pressure dramatically in hypertension. Vitamin C improves the endothelial activity in diabetes patients and smokers when injected intra-arterially. Many who smoke tobacco have a lower amount of vitamin C in their plasma and leukocytes [38].

Chronic inflammation is exacerbated by vitamin C injections of hypercholesterolemia patients (possibly due to oxidative stress). Fifteen days of oral vitamin C treatment increases endothelium-dependent vasoconstriction in patients with heart failure, and even a single injection of 2 g will enhance vasoconstriction activity. Although it's unknown if heart failure patients have lower vitamin C levels, research shows that the aged are deficient. Vitamin C has been found to assist with endothelial damage in patients with heart disease [39].

Folate

Folate is capable of transforming homocysteine to methionine, and both hyperhomocysteinemia and non-hyperhomocysteinemia patients have a clear inverse relationship between folate consumption and homocysteine concentrations. Tissue amounts of vitamin B12, B6, and folate are not equivalent to blood sugar levels, and far more older patients may be impaired than previously thought. As per epidemiological data, there is an inverse association between folate consumption along with the risk of acute myocardial infarction [40].

Homocysteine and congenital heart disease

Homocysteine synthesis is how most vitamins bind with one another (fig. 1). Hyperhomocysteinemia is a key cause of cardiovascular disease. Just 12 percent just above the upper limit of average is associated with a threefold rise in the probability of AMI [41].



Fig. 1: Homocysteine metabolism

DISCUSSION

Several reviews show that persistent along with cardiovascular disease are frequently inadequate in essential nutrients. Poor nutrition may lead to reduced left ventricular activity, negative impact on the patient, and people suffer, all of which contribute to the development of chronic heart failure. Micronutrient intake, on the other hand, is used in significantly reduced trials. Micronutrient intake is also seen in research to also be useful for individuals along with cardiovascular disease and to get a positive impact. Seeing as conventional therapies aren't completely effective, there is still a pressing must to reduce mortality in chronic heart failure patients.

Coenzyme Q10 is shown to reduce cardiac-related death, improve health, improve overall work power, and improve Left ventricular expulsion fraction. Supplementing with vitamin D lowers cardiac death, improves Left ventricular ejection fraction, improves New York Heart Association classification, and improves overall strength. Homocysteine has also been found to get a detrimental increased risk of cardiac function. Vitamin B supplements, especially folic acid, have been related to lower homocysteine and thus reduced cardiovascular disease effects. Micronutrients have been shown in trials to boost not only Left ventricular activity and also well-being in people with chronic heart failure.

CONCLUSION

While the accumulation of data indicates that nutrition may indicate a vital role in heart failure, there have still been a few areas of concern to be addressed. To begin with, the great majority of current data. Prospective studies, which necessitate the use of broader clinical studies second, the bulk of the studies cited were undertaken at a time when no proof medical procedures were available. Future studies could concentrate on the additional benefits of comprehensive, instead of individual, micronutrient supplements in the form of heart failure guideline-recommended treatment, with this easily available evidence serving as a basis for broader epidemiological studies.

FUNDING

Nil

AUTHORS CONTRIBUTIONS

All the authors have contributed equally.

CONFLICTS OF INTERESTS

Declared none

REFERENCES

1. Buttar HS, Li T, Ravi N. Prevention of cardiovascular diseases: role of exercise, dietary interventions, obesity and smoking cessation. Exp Clin Cardiol. 2005;10(4):229-49. PMID 19641674.
2. Nakhaee S, Ghasemi S, Karimzadeh K, Zamani N, Alinejad-Mofrad S, Mehrpour O. The effects of opium on the cardiovascular system: a review of side effects, uses, and potential mechanisms. Subst Abuse Treat Prev Policy. 2020 Dec;15(1):30. doi: 10.1186/s13011-020-00272-8, PMID 32303254.
3. Anand SS, Hawkes C, De Souza RJ, Mente A, Dehghan M, Nugent R, Zulyniak MA, Weis T, Bernstein AM, Krauss RM, Kromhout D, Jenkins DJA, Malik V, Martinez-Gonzalez MA, Mozaffarian D, Yusuf S, Willett WC, Popkin BM. Food Consumption and its Impact on Cardiovascular Disease: Importance of Solutions Focused on the Globalized Food System: A Report From the Workshop Convened by the World Heart Federation. J Am Coll Cardiol. 2015 Oct 6;66(14):1590-614. doi: 10.1016/j.jacc.2015.07.050, PMID 26429085.
4. Riegel B, Moser DK, Buck HG, Dickson VV, Dunbar SB, Lee CS, Lennie TA, Lindenfeld J, Mitchell JE, Treat‐Jacobson DJ, Webber DE, American Heart Association Council on Cardiovascular and Stroke Nursing; Council on Peripheral Vascular Disease; and Council on Quality of Care and Outcomes Research. Self-care for the prevention and management of cardiovascular disease and stroke: A scientific statement for healthcare professionals from the American Heart Association. J Am Heart Assoc. 2017 Aug 31;6(9):e006997. doi: 10.1161/JAHA.117.006997, PMID 28860232.
5. Mozaffarian D. Dietary and policy priorities for cardiovascular disease, diabetes, and obesity: a comprehensive review. Circulation. 2016 Jan 12;133(2):187-225. doi: 10.1161/CIRCULATIONAHA.115.018585, PMID 26746178.
6. Jensen S, Yates B, Lyden E, Hanson C. Micronutrient intake of participants in a "partners together in health" cardiac rehab intervention. J Acad Nutr Diet. 2017 Sep 1;117(9):A59. doi: 10.1016/j.jand.2017.06.178.
7. Bonucchi J, Hassan I, Policeni B, Kaboli P. Thyrotoxicosis associated Wernicke's encephalopathy. J Gen Intern Med. 2008 Jan 1;23(1):106-9. doi: 10.1007/s11606-007-0438-3, PMID 18026802.
8. Milne I. Who was James Lind, and what exactly did he achieve. J R Soc Med. 2012 Dec;105(12):503-8. doi: 10.1258/jrsm.2012.12k090, PMID 23288083.
9. Zhang R, Naughton DP. Vitamin D in health and disease: current perspectives. Nutr J. 2010 Dec;9:65. doi: 10.1186/1475-2891-9-65, PMID 21143872.

10. Izzo M, Carrizzo A, Izzo C, Cappello E, Cecere D, Ciccarelli M, Iannece P, Damato A, Vecchione C, Pompeo F. Vitamin D: not just bone metabolism but a key player in cardiovascular diseases. Life (Basel). 2021 May;11(5):452. doi: 10.3390/life11050452, PMID 34070202.
11. Martens PJ, Gysemans C, Verstuyf A, Mathieu AC. Vitamin D's effect on immune function. Nutrients. 2020 May;12(5):1248. doi: 10.3390/nu12051248, PMID 32353972.
12. Bittker SS. Elevated levels of 1, 25-dihydroxyvitamin D in plasma as a missing risk factor for celiac disease. Clin Exp Gastroenterol. 2020;13:1-15. doi: 10.2147/CEG.S222353, PMID 32021373.
13. Anderson PH, May BK, Morris HA. Vitamin D metabolism: new concepts and clinical implications. Clin Biochem Rev. 2003 Feb;24(1):13-26. PMID 18650961.
14. Lugg ST, Howells PA, Thickett DR. Optimal vitamin D supplementation levels for cardiovascular disease protection. Dis Markers. 2015 Sep 8;2015:864370. doi: 10.1155/2015/864370, PMID 26435569.
15. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D'Agostino RB, Wolf M, Vasan RS. Vitamin D Deficiency and Risk of Cardiovascular Disease. Circulation. 2008;117(4):503-11. doi: 10.1161/CIRCULATIONAHA.107.706127.
16. Sosa Henríquez M, Gómez de Tejada Romero MJ. Cholecalciferol or calcifediol in the management of vitamin D deficiency. Nutrients. 2020 Jun;12(6):1617. doi: 10.3390/nu12061617, PMID 32486496.
17. DiNicolantonio JJ, Niazi AK, Lavie CJ, O'Keefe JH, Ventura HO. Thiamine supplementation for the treatment of heart failure: a review of the literature. Congest Heart Fail. 2013 Jul;19(4):214-22. doi: 10.1111/chf.12037, PMID 23910704.
18. Helali J, Park S, Ziaeian B, Han JK, Lankarani-Fard A. Thiamine and heart failure: challenging cases of modern-day cardiac beriberi. Mayo Clin Proc Innov Qual Outcomes. 2019 Jun 1;3(2):221-5. doi: 10.1016/j.mayocpiqo.2019.03.003, PMID 31193878.
19. Kibirige D, Mwebaze R. Vitamin B12 deficiency among patients with diabetes mellitus: is routine screening and supplementation justified? J Diabetes Metab Disord. 2013 Dec;12(1):17. doi: 10.1186/2251-6581-12-17, PMID 23651730.
20. Moretti R, Peinkhofer C. B vitaminS and fatty acids: what do they share with small vessel disease-related dementia? Int J Mol Sci. 2019 Jan;20(22):5797. doi: 10.3390/ijms20225797, PMID 31752183.
21. Saini R. Coenzyme Q10:The essential nutrient. J Pharm Bioallied Sci. 2011 Jul 1;3(3):466-7. doi: 10.4103/0975-7406.84471, PMID 21966175.
22. Zozina VI, Covantev S, Goroshko OA, Krasnykh LM, Kukes VG. Coenzyme Q10 in cardiovascular and metabolic diseases: current state of the problem. Curr Cardiol Rev. 2018 Aug 1;14(3):164-74. doi: 10.2174/1573403X14666180416115428, PMID 29663894.
23. Belardinelli R, Muçaj A, Lacalaprice F, Solenghi M, Seddaiu G, Principi F, Tiano L, Littarru GP. Coenzyme Q10 and exercise training in chronic heart failure. Eur Heart J. 2006 Nov 1;27(22):2675-81. doi: 10.1093/eurheartj/ehl158, PMID 16882678.
24. Fotino AD, Thompson-Paul AM, Bazzano LA. Effect of coenzyme Q_{10} supplementation on heart failure: a meta-analysis. Am J Clin Nutr. 2013 Feb 1;97(2):268-75. doi: 10.3945/ajcn.112.040741, PMID 23221577.
25. Di Lorenzo A, Iannuzzo G, Parlato A, Cuomo G, Testa C, Coppola M, D'Ambrosio G, Oliviero DA, Sarullo S, Vitale G, Nugara C, Sarullo FM, Giallauria F. Clinical evidence for Q10 coenzyme supplementation in heart failure: from energetics to functional improvement. J Clin Med. 2020 May;9(5):1266. doi: 10.3390/jcm9051266, PMID 32349341.
26. Lei L, Liu Y. Efficacy of coenzyme Q10 in patients with cardiac failure: a meta-analysis of clinical trials. BMC Cardiovasc Disord. 2017 Dec;17(1):196. doi: 10.1186/s12872-017-0628-9, PMID 28738783.
27. Li Y, Fitzgibbons TP, McManus DD, Goddeau Jr RP, Silver B, Henninger N. Left ventricular ejection fraction and clinically defined heart failure to predict 90-day functional outcome after ischemic stroke. J Stroke Cerebrovasc Dis. 2019 Feb 1;28(2):371-80. doi: 10.1016/j.jstrokecerebrovasdis.2018.10.002, PMID 30396839.
28. Patel J, Sandhu A, Parizo J, Moayedi Y, Fonarow GC, Heidenreich PA. Validity of performance and outcome measures for heart failure. Circ Heart Fail. 2018 Sep;11(9):e005035. doi: 10.1161/CIRCHEARTFAILURE.118.005035, PMID 30354367.
29. Savarese G, Lund LH. Global Public Health Burden of Heart Failure. Card Fail Rev. 2017;3(1):7-11. doi: 10.15420/cfr.2016:25:2. PMID 28785469.
30. Bagheri B, Akbari N, Tabiban S, Habibi V, Mokhberi V. Serum level of copper in patients with coronary artery disease. Niger Med J. 2015 Jan;56(1):39-42. doi: 10.4103/0300-1652.149169, PMID 25657492.
31. Kheiri B, Abdalla A, Osman M, Ahmed S, Hassan M, Bachuwa G. Vitamin D deficiency and risk of cardiovascular diseases: a narrative review. Clin Hypertens. 2018 Dec;24:9. doi: 10.1186/s40885-018-0094-4, PMID 29977597.
32. Kurutas EB. The importance of antioxidants which play a role in cellular response against oxidative/nitrosative stress: current state. Nutr J. 2016 Dec;15(1):71. doi: 10.1186/s12937-016-0186-5, PMID 27456681.
33. Flanagan JL, Simmons PA, Vehige J, Willcox MD, Garrett Q. Role of carnitine in disease. Nutrition and mMetabolism. 2010 Dec; 7:1-4.
34. Sada H, Kato A, Sumimoto R, Ohmori H, Ohdan H. Effects of L-carnitine supplementation on nutritional, immunological, and cardiac parameters in hemodialysis patients: a pilot study. Renal Replacement Therapy. 2015 Dec; 1:1-8.
35. Song X, Qu H, Yang Z, Rong J, Cai W, Zhou H. Efficacy and safety of L-carnitine treatment for chronic heart failure: a meta-analysis of randomized controlled trials. BioMed research international. 2017 Apr 13;2017:6274854. doi: 10.1155/2017/6274854, PMID 28497060.
36. Fielding R, Riede L, Lugo JP, Bellamine A. L-carnitine supplementation in recovery after exercise. Nutrients. 2018 Mar; 10(3):349. doi: 10.3390/nu10030349, PMID 29534031.
37. Chen GC, Lu DB, Pang Z, Liu QF. Vitamin C intake, circulating vitamin C and risk of stroke: a meta-analysis of prospective studies. Journal of the American Heart Association. 2013 Nov 27;2(6):e000329. doi: 10.1161/JAHA.113.000329, PMID 24284213.
38. Juraschek SP, Guallar E, Appel LJ, Miller III ER. Effects of vitamin C supplementation on blood pressure: a meta-analysis of randomized controlled trials. The American journalJ of cClinical nNutrition. 2012 May 1;95(5):1079-88. doi: 10.3945/ajcn.111.027995, PMID 22492364.
39. Tan BL, Norhaizan ME, Liew WP, Sulaiman Rahman H. Antioxidant and oxidative stress: a mutual interplay in age-related diseases. Frontiers in pPharmacology. 2018 Oct 16;9:1162. doi: 10.3389/fphar.2018.01162, PMID 30405405.
40. Tinelli C, Di Pino A, Ficulle E, Marcelli S, Feligioni M. Hyperhomocysteinemia as a risk factor and potential nutraceutical target for certain pathologies. Frontiers in nNutrition. 2019 Apr 24;6:49. doi: 10.3389/fnut.2019.00049, PMID 31069230.
41. Ganguly P, Alam SF. Role of homocysteine in the development of cardiovascular disease. Nutr. J. 2015;14:6.